It is made possible through a first-of-a-kind integration with Eli Lilly’s direct-to-consumer website, and aims to streamline access to the popular treatment.

Zepbound, a drug with the main active ingredient tirzepatide, was found to be more helpful in helping people lose weight than Wegovy, a drug with the main active ingredient semaglutide, according to new data released Wednesday by Eli Lilly, the maker of Zepbound.

Telehealth company Ro said on Wednesday it will provide access to single-dose vials of Eli Lilly's weight-loss drug Zepbound to patients with obesity.